A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

NCT07527910 on ClinicalTrials.gov · last registry update 2026-09-29

Recruiting now, toward 204 participants. Due to report 15 March 2030, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Percent change in liver fat. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Regeneron Pharmaceuticals
Sponsor type: Industry
Enrollment: 204
Started: 2026-05-22
Primary completion: 2030-03-15 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent change in liver fat

Conditions studied

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.